Navigation Links
HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection

Researchers at the Tulane University School of Medicine, New Orleans, Louisiana have discovered that the HIV-1 protease inhibitors (PIs), such as nelfinavir included in highly active antiretroviral therapy (HAART) regimen for the treatment of HIV-1 patients, induce deleterious effects on insulin secretion mediated through the oxidative stress pathway. They report a significant decrease in the levels of the antioxidants, cytosolic superoxide dismutase (Cu/Zn SOD) and glutathione, whereas mitochondrial SOD levels remained unaffected in pancreatic beta-cells (INS-1 cells) exposed to nelfinavir. However, the mitochondrial uncoupling protein (UCP2) levels were up-regulated during nelfinavir induced oxidative stress and directly affected the ATP levels in these cells. A significant decrease in ATP production was also observed which may account for the decrease in glucose stimulated insulin secretion upon nelfinavir treatment. This study appears in the April 2009 issue of Experimental Biology and Medicine. Although insulin resistance has been clinically observed in HIV-1 patients receiving HAART regimen, the molecular mechanisms of this metabolic abnormality have not been delineated.

The research team led by Dr. Krishna C. Agrawal, Regents Professor and Chairman included Surabhi Chandra, a graduate student and another faculty member, Dr. Debasis Mondal in the Department of Pharmacology. These investigators successfully tested the hypothesis that nelfinavir induced oxidative stress was responsible for the deleterious effects of the HIV-1 protease inhibitor on insulin production by pancreatic beta-cells and they further investigated the therapeutic strategies to ameliorate the insulin dysregulation at this level. Since the hypoglycemic effects of Nigella sativa oil have been investigated in the past, the investigators postulated that nelfinavir induced oxidative stress may be ameliorated by the administration of the active ingredient of this oil, thymoquinone. Furthermore, it was envisioned that since thymoquinone shares a structural homology with ubiquinone (mitochondrial component) it is likely that it may act as a mitochondrial antioxidant. Indeed pretreatment of pancreatic beta-cells with thymoquinone caused a reversal of nelfinavir induced deleterious effects. Thymoquinone decreased the production of reactive oxygen species, increased the Cu/Zn SOD and glutathione levels, suppressed the UCP-2 protein levels and restored nelfinavir induced decrease in insulin secretion to normal levels in these cells. Dr. Agrawal commented, "An important finding of this study is that the dysregulation of insulin production in pancreatic beta-cells is due to generation of reactive oxygen species induced by nelfinavir, an HIV-1 protease inhibitor". Furthermore, Dr. Agrawal said, "thymoquinone, an antioxidant provided a significant protection to pancreatic beta-cells from the toxic effects of nelfinavir and therefore these findings clearly suggest a potential role for the use of black seed oil or thymoquione as a protective agent against HIV-1 protease inhibitor induced deleterious effects on pancreatic beta-cells".


Contact: Dr. Krishna C. Agrawal
Society for Experimental Biology and Medicine

Related biology news :

1. Rebuilding the evolutionary history of HIV-1 unravels a complex loop
2. Mutant host cell protein sequesters critical HIV-1 element
3. Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment
4. New inhibitor has potential as cancer drug
5. New research shows no link between aromatase inhibitors and cardiovascular problems
6. New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
7. Scientists identify novel inhibitor of human microRNA
8. Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes
9. Feeling hot, hot, hot: New study suggests ways to control fever-induced seizures
10. SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma
11. New technique reveals subtle force-induced changes in biomolecules conformation
Post Your Comments:
(Date:11/12/2015)... Nov. 11, 2015   Growing need for ... tools has been paving the way for use ... of discrete analytes in clinical, agricultural, environmental, food ... predominantly used in medical applications, however, their adoption ... due to continuous emphasis on improving product quality ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
Breaking Biology Technology: